IBD patients on thiopurine and allopurinol did not have a statistically significant different risk of adverse outcomes (including initiation of a biologic) when compared with IBD patients exposed to thiopurine monotherapy. This conclusion is based on an analysis of a nationwide cohort of Danish IBD patients who had been prescribed thiopurine therapy between 1999 and 2014 .
In this period, 10,367 patients with IBD (5,484 Crohn’s disease and 4,883 ulcerative colitis) were prescribed thiopurines; 217 of them used allopurinol co-therapy. The primary outcome was a composite of any adverse outcome or need for biological treatment: IBD-related hospitalisation, IBD-related surgery, biological therapy initiation, or death. In patients exposed to allopurinol co-therapy, there were 40 incident outcomes in 129 person-years (PY) (incidence rate 310.1 per 1,000 PY). In patients exposed to thiopurine monotherapy, 4,745 outcomes among 24,585 PY were observed (incidence...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« ZNF133 associated with infliximab response Next Article
OPERA II study: MAdCAM-1 antibody SHP647 »
Table of Contents: ECCO 2019
New Compounds: Study Results
Short-term and Long-term Treatment Results
Complementary and Alternative Medicine
Basic and Preclinical Research
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.